The estimated Net Worth of Robert I Blum is at least $30.1 million dollars as of 3 September 2024. Mr. Blum owns over 5,000 units of Cytokinetics Inc stock worth over $21,640,059 and over the last 20 years he sold CYTK stock worth over $4,953,357. In addition, he makes $3,475,980 as President, Chief Executive Officer et Director at Cytokinetics Inc.
Robert has made over 123 trades of the Cytokinetics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of CYTK stock worth $33,350 on 3 September 2024.
The largest trade he's ever made was exercising 83,332 units of Cytokinetics Inc stock on 18 February 2021 worth over $784,987. On average, Robert trades about 4,683 units every 11 days since 2005. As of 3 September 2024 he still owns at least 402,456 units of Cytokinetics Inc stock.
You can see the complete history of Mr. Blum stock trades at the bottom of the page.
Robert I. Blum is President, Chief Executive Officer, Director of the Company. Mr. Blum was appointed as our President and Chief Executive Officer and as a member of our Board of Directors in January 2007. Previous to that appointment, Mr. Blum served as our President from February 2006 to January 2007. He served as our Executive Vice President, Corporate Development and Commercial Operations and Chief Business Officer from September 2004 to February 2006. From January 2004 to September 2004, he served as our Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From October 2001 to December 2003, he served as our Senior Vice President, Corporate Development and Finance and Chief Financial Officer. From July 1998 to September 2001, Mr. Blum was our Vice President, Business Development. Prior to joining us in July 1998, he was Director, Marketing at COR Therapeutics, Inc. since 1996. From 1991 to 1996, he was Director, Business Development at COR Therapeutics. Prior to that, Mr. Blum performed roles of increasing responsibility in sales, marketing and other pharmaceutical business functions at Marion Laboratories, Inc. and Syntex Corporation. Mr. Blum has served as Chairman of the Board of Directors of Gamida Cell Ltd. since September 2018. Mr. Blum received B.A. degrees in Human Biology and Economics from Stanford University and an M.B.A. from Harvard Business School. Mr. Blum brings to our Board of Directors a deep familiarity with our operations, strategy and vision, as well as a record of successful corporate management, strategic partnering and financing.
As the President, Chief Executive Officer et Director of Cytokinetics Inc, the total compensation of Robert Blum at Cytokinetics Inc is $3,475,980. There are no executives at Cytokinetics Inc getting paid more.
Robert Blum is 56, he's been the President, Chief Executive Officer et Director of Cytokinetics Inc since 2007. There are 16 older and 3 younger executives at Cytokinetics Inc. The oldest executive at Cytokinetics Inc is Dr. James A. Spudich Ph.D., 79, who is the Co-Founder & Member of Scientific Advisory Board.
Robert's mailing address filed with the SEC is 350 OYSTER POINT BLVD, , SOUTH SAN FRANCISCO, CA, 94080.
Over the last 21 years, insiders at Cytokinetics Inc have traded over $50,353,277 worth of Cytokinetics Inc stock and bought 879,922 units worth $7,454,506 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Capital Ltd Portfolio Servi... et Partners L P/Ilbiotechnolog.... On average, Cytokinetics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,225,580. The most recent stock trade was executed by B Lynne Parshall on 9 September 2024, trading 5,000 units of CYTK stock currently worth $108,050.
cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. as a leader in muscle biology and the mechanics of muscle performance, we're developing small molecule drug candidates specifically engineered to increase muscle function and contractility.
Cytokinetics Inc executives and other stock owners filed with the SEC include: